Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q3 FY22 results · Oct–Dec 2021
Suven Life Sciences reported revenue from operations of ₹4.43 crore (up 193.0% from Q3 FY21) and net loss of ₹33.69 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4.43 | 1.51 | +193.0% | 1.18 | +274.4% |
| Other income | 0.14 | 1.62 | −91.3% | 0.50 | −72.0% |
| Total income | 4.57 | 3.14 | +45.8% | 1.69 | +171.1% |
| Profit before tax | (33.69) | (26.30) | Loss widened | (28.30) | Loss widened |
| Net profit for the period | (33.69) | (24.39) | Loss widened | (28.30) | Loss widened |
| EPS, basic (₹) | (2.65) | (1.92) | Loss widened | (2.22) | Loss widened |
| Net margin (%) | -760.0 | -1612.2 | -2389.8 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4.43 | 1.51 | +193.0% | 1.18 | +274.4% |
| Other income | 0.14 | 1.62 | −91.3% | 0.50 | −72.0% |
| Total income | 4.57 | 3.14 | +45.8% | 1.69 | +171.1% |
| Profit before tax | (8.22) | (10.05) | Loss narrowed | (10.98) | Loss narrowed |
| Net profit for the period | (8.22) | (8.15) | Loss widened | (10.98) | Loss narrowed |
| EPS, basic (₹) | (0.65) | (0.64) | Loss widened | (0.86) | Loss narrowed |
| Net margin (%) | -185.4 | -538.5 | -927.5 |
Consolidated
- Filed with BSE
- 31 Jan 2022, 18:39 IST
- Board meeting
- 31 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2022, 18:39 IST
- Board meeting
- 31 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE